secwatch.observer — SEC 8-K summary
======================================

Issuer:     DermTech, Inc. (—)
CIK:        0001651944
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001651944-24-000044
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DermTech Q1 revenue up 11% to $3.8M; net loss narrows to $20M
-------------------------------------------------------------

- Test revenue $3.7M (+7% YoY); billable sample volume ~15,360 (-14% YoY).
- Net loss $20.0M ($0.58/share) vs. $31.3M ($1.02/share) in Q1 2023.
- Test gross margin improved to 16% from -11% YoY on 19% lower cost of test revenue.
- Sales & marketing expenses down 49% to $7.8M; G&A down 15% to $10.1M.
- Cash, equivalents and marketable securities $42.4M at March 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651944/000165194424000044/0001651944-24-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651944/000165194424000044/dmtk-20240514.htm
  HTML page:      https://secwatch.observer/filing/0001651944-24-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer